The Association of the British Pharmaceutical Industry (ABPI) is calling for a cross-sector response across healthcare, academia and the pharmaceutical industry to navigate and harness the potential of ‘big data’ to improve patient care and maximise the opportunities for investment in the UK.
The call to action is the focus of the ABPI’s newly launched ‘big data’ road map which is a four-point plan to direct progress over the next four years. The four areas of focus in the plan are: increasing awareness; building capabilities and capacity; creating sustainable data ecosystems; and accelerating high-value opportunities.
The road map clearly articulates the scale and volume of ‘big data’ available, breaking it down into five topics ¹, and calls for a shift in the balance from volume to value. It gives a clear vision of the future possibilities within the life sciences and healthcare spanning the full value chain from drug discovery to healthcare delivery. Future possibilities that are highlighted in the road map include enhanced therapeutic target identification, virtual drug design, modelling stratified medicines and patient pathway redesign.
Bina Rawal, Medical, Innovation & Research Director for the ABPI, said:
“The ABPI is a proud partner to the research community in the UK. One way we can make the UK a more attractive environment is to fully harness the unique ‘big data’ opportunities available in the UK. The ‘big data’ road map is a starting point to build the UK’s potential for world-class data-led research and innovation-driven healthcare delivery.
“No one organisation or sector can address these opportunities alone and, if we are going to leverage ‘big data’ for the benefits of patients, the industry, academia and the wider healthcare system must develop new collaborations and partnerships to tackle the challenges together.”
Health Minister Lord Howe said:
“Using data better will bring huge opportunities to develop improved treatments for patients. I am pleased that the ABPI’s ‘big data’ road map is setting out a vision and providing a valuable opportunity for Government, industry, NHS, academia and research professionals to contribute their perspectives and experience to the debate.”
The potential of ‘big data’ is the focus of the ABPI annual research and development conference, ‘360° of Health Data: Harnessing Big Data for Better Health’, which is hosted in partnership with the National Institute for Health Research (NIHR). The conference is taking place today involving over 280 delegates from across healthcare, academia and the pharmaceutical industry.
ABPI commissioned advisory firm KPMG to produce the ‘big data’ road map in partnership with them
¹Within the road map, data is broken down to five areas:
1. Healthcare data, such as prescriptions, compliance and response pattern
2. Genetic and genomic data, such as 100k Genome Project and Biobank data
3. Automated sensors and smart devices, such as dosage monitoring apps and digital pills
4. Self-generated data and digital engagement, such as social media and patient forums for sharing experiences
5. Public Data Releases, such as commissioning data and aggregated population health data